Choice of treatment options for metastatic hormone-sensitive prostate cancer

The arsenal of available treatments and treatments for metastatic hormone-sensitive prostate cancer (mHRPC) has increased significantly over the past 5 years. Although androgen-preferential therapy (ADT) remains the mainstay of treatment, the addition of docetaxel, abiraterone, enzalutamide, apalutamide, or local external beam radiation therapy improves the outcome of patients with mHRPC and becomes the standard of care. Choosing a therapy to improve treatment outcomes for patients with mHRPC is becoming increasingly challenging as there are different options for this stage of the disease. This article provides an overview of clinical trials that included ADT in combination with chemotherapy, new hormonal therapy, and radiation therapy. We will also consider recent advances in the choice of treatment for men diagnosed with mHPCR and the impact of previous therapy on the subsequent biology of the disease. Options include chemohormone therapy, androgen receptor (AR) targeted therapy in addition to ADT or, less commonly, ADT alone. The choice of treatment should be based on a consideration of the clinical characteristics and characteristics of the disease, as well as taking into account the patient’s preferences, territorial constraints and financial resources.

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi: 10.3322/caac.21590.

2. Herlemann A., Washington S.L., Cooperberg M.R. Health care delivery for metastatic hormone-sensitive prostate cancer across the globe. Eur Urol Focus. 2019;5(2):155–158. doi: 10.1016/j.euf.2018.12.003.

3. Gafanov R.A. Hormonal therapy and chemotherapy in patients with hormone-sensitive prostate cancer. Onkourologiya = Cancer Urology. 2016;12(1):63–68. (In Russ.) doi: 10.17650/1726-9776-2016-12-1-63-68.

4. Pavlov A.Yu., Gafanov R.A., Tsybul’skiy A.D., Fastovets S.V., Kravtsov I.B. Modern strategy of drug therapy for metastatic and castrate-resistant prostate cancer. RMZh = RMJ. 2016;(8):476–479. (In Russ.) Available at: https://www.rmj.ru/articles/urologiya/Sovremennaya_strategiya_lekarst- vennoy_terapiimetastaticheskogo_i_kastracionno-rezistentnogo_raka_predstatelynoy_ghelezy.

5. Gafanov R.A., Dzidzaria A.G., Kravtsov I.B., Fastovets S.V. Metastatic hormone-sensitive prostate cancer: Practical guidelines and optimization of therapy selection. Onkourologiya = Cancer Urology. 2018;14(4):139–149. (In Russ.) doi: 10.17650/1726-9776-2018-14-4-139-149.

6. Kharchenko V.P., Kaprin A.D., Gafanov R.A., Kostin A.A. Hormone-resistant prostate cancer. Treatment options. Andrologiya i genital’naya khirurgiya = Andrology and Genital Surgery. 2001;2(4):8–12. (In Russ.)

7. Kharchenko V.P., Kaprin A.D., Gafanov R.A., Kostin A.A., Podshivalov A.V. Chemotherapy for hormone-resistant prostate cancer. In: Abstracts of the 1st Congress of the Professional Association of Andrologists of Russia. Kislovodsk; 2001, рp. 35–36. (In Russ.)

8. Lee D.J., Mallin K., Graves A.J., Chang S.S., Penson D.F., Resnick M.J., Barocas D.A. Recent changes in prostate cancer screening practices and epidemiology. J Urol. 2017;198(6):1230–1240. doi: 10.1016/j.juro.2017.05.074.

9. Gravis G., Fizazi K., Joly F., Oudard S., Priou F., Esterni B. et al. Androgendeprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149–158. doi: 10.1016/S1470-2045(12)70560-0.

10. Gravis G., Boher J.M., Joly F., Soulié M., Laurence Albiges L., Priou F. et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70(2):256–262. doi: 10.1016/j. eururo.2015.11.005.

11. Sweeney C.J., Chen Y.H., Carducci M., Liu G., Jarrard D.F., Eisenberger M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746. doi: 10.1056/NEJMoa1503747.

12. Eisenberger M., Crawford E., Wolf M., Blumenstein B., McLeod D., Benson R. et al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. Semin Oncol. 1994;21(5):613–619. Available at: https://pubmed.ncbi.nlm.nih.gov/7939752.

13. Kyriakopoulos C.E., Chen Y.H., Carducci M., Liu G., Jarrard D.F., Hahn N.M. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 chaarted trial. J Clin Oncol. 2018;36(11):1080–1087. doi: 10.1200/JCO.2017.75.3657.

14. Gravis G., Boher J.M., Chen Y.H., Liu G., Fizazi K., Carducci M.A. et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur Urol. 2018;73(6):847–855. doi: 10.1016/j.eururo.2018.02.001.

15. James N.D., Sydes M.R., Clarke N.W., Mason M.D., Dearnaley D.P., Spears M.R. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–1177. doi: 10.1016/S0140-6736(15)01037-5.

16. Clarke N., Ali A., Ingleby F.C., Hoyle A., Amos C.L., Attard G. et al. Addition of docetaxel to hormonal therapy in lowand high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019;30(12):1992–2003. doi: 10.1093/annonc/mdz396.

17. Templeton A.J., Vera-Badillo F.E., Wang L., Attalla M., De Gouveia P., Leibowitz-Amit R. et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol. 2013;24(12):2972–2977. doi: 10.1093/annonc/mdt397.

18. James N.D., de Bono J.S., Spears M.R., Clarke N.W., Mason M.D., Dearnaley D.P. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–351. doi: 10.1056/NEJMoa1702900.

19. Becker P.S., Griffiths E.A., Alwan L.M., Bachiashvili K., Brown A., Cool R. et al. NCCN guidelines insights: hematopoietic growth factors, version 1.2020. J Natl Compr Canc Netw. 2020;18(1):12–22. doi: 10.6004/jnccn.2020.0002.

20. Rush H., Cook A.D., Brawley C.D., Murphy L., Macnair A., Millman R. et al. Comparative quality of life in patients randomized contemporaneously to docetaxel or abiraterone in the STAMPEDE trial. J Clin Oncol. 2020;38(6S). doi: 10.1200/jco.2020.38.6_suppl.14.

21. Bumbaca B., Li W. Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies. Acta Pharm Sin B. 2018;8(4):518–529. doi: 10.1016/j.apsb.2018.04.007.

22. Mahon K.L., Qu W., Lin H.M., Spielman C., Cain D., Jacobs C. et al. Serum free methylated glutathione S-transferase 1 DNA levels, survival, and response to docetaxel in metastatic, castration-resistant prostate cancer: post hoc analyses of data from a phase 3 trial. Eur Urol. 2019;76(3):306– 312. doi: 10.1016/j.eururo.2018.11.001.

23. Mahon K., Lin H., Lee-Ng M., Cain D., Jacobs C., Stockler M. et al. Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37(7S). doi: 10.1200/jco.2019.37.7_suppl.230.

24. Choueiri T.K., Xie W., D’Amico A.V., Ross R.W., Hu J.C., Pomerantz M. et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009;115(5):981–987. doi: 10.1002/cncr.24064.

25. Flanagan J., Kathryn Gray P., Hahn N., Hayes J., Myers L.J., Carney- Doebbeling C., Sweeney C.J. Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol. 2011;22(4):801–807. doi: 10.1093/annonc/mdq443.

26. Sharma J., Gray K.P., Evan C., Nakabayashi M., Fichorova R., Rider J. et al. Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate. 2014;74(3):225–234. doi: 10.1002/pros.22744.

27. Zhao S.G., Laura Chang S.L., Erho N., Yu M., Lehrer J., Alshalalfa M. et al. Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy. JAMA Oncol. 2017;3(12):1663–1672. doi: 10.1001/jamaoncol.2017.0751.

28. Hamid A., Wang X.V., Chen Y.H., Feng F.Y., Benjamin Den R., Attard G. et al. Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): a correlative study of E3805 CHAARTED. J Clin Oncol. 2020;38(6S):160– 162. doi: 10.1200/jco.2020.38.6_suppl.162.

29. Gillessen S., Attard G., Beer T.M., Beltran H., Bossi A., Bristow R. et al. Management of patients with advanced prostate cancer: the Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018;73(2):178–211. doi: 10.1016/j.eururo.2017.06.002.

30. Mohler J.L., Antonarakis E.S., Armstrong A.J., D’Amico A.V., Davis B.J., Dorff T. et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(5):479–505. doi: 10.6004/jnccn.2019.0023.

31. Heidenreich A., Bastian P.J., Bellmunt J., Bolla M., Joniau S., van der Kwast T. et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–479. doi: 10.1016/j.eururo.2013.11.002.

32. Fizazi K., Tran N., Fein L., Matsubara N., Rodriguez-Antolin A., Alekseev B.Y. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–360. doi: 10.1056/NEJMoa1704174.

33. Davis I.D., Martin A.J., Stockler M.R., Begbie S., Chi K.N., Chowdhury S. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121–131. doi: 10.1056/NEJMoa1903835.

34. Armstrong A., Szmulewitz R., Petrylak D., Villers A., Azad A., Alcaraz A. et al. Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): the ARCHES trial. J Clin Oncol. 2019;37(7):687. doi: 10.1200/JCO.2019.37.7_suppl.687.

35. Chi K.N., Agarwal N., Bjartell A., Chung B.H., Pereira de Santana Gomes A.J., Given G. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;38(1)1:13–24. doi: 10.1056/NEJMoa1903307.

36. Armstrong A.J., Szmulewitz R.Z., Petrylak D.P., Holzbeierlein J., Villers A., Azad A. et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974–2986. doi: 10.1200/JCO.19.00799.

37. Agarwal N., Chowdhury S., Bjartell A., Chung B., Gomes A., Given R. et al. Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane). J Clin Oncol. 2020;38(6 Suppl.):82–89. doi: 10.1200/JCO.2020.38.6_suppl.82.

38. Gillessen S., Attard G., Beer T.M., Beltran H., Bjartell A., Bossi A. et al. Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77(4):508–547. doi: 10.1016/j.eururo.2020.01.012.

39. Lu-Yao G., Nikita N., Keith S.W., Nightingale G., Gandhi K., Hegarty S.E. et al. Mortality and hospitalization risk following oral androgen signaling inhibitors among men with advanced prostate cancer by pre-existing cardiovascular comorbidities. Eur Urol. 2020;77(2):158–166. doi: 10.1016/j.eururo.2019.07.031.

40. Khalaf D.J., Sunderland K., Eigl B.J., Kollmannsberger C.K., Ivanov N., Finch D.L. et al. Health-related quality of life for abiraterone plus prednisone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: results from a phase II randomized trial. Eur Urol. 2019;75(6):940–947. doi: 10.1016/j.eururo.2018.12.015.

41. Penson D.F. Keynote: Financial toxicity and quality of life: understanding and improving patient­centered outcomes in genitourinary malignancies. Available at: https://meetinglibrary.asco.org/record/180842/video.

42. Parker C., James N., Brawley C., Clarke N., Hoyle A., Ali A. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392(10162):2353–2366. doi: 10.1016/S0140-6736(18)32486-3.

43. Halabi S. Subgroup analysis in clinical trials. Paper presented at: Advanced Prostate Cancer Consensus Conference; August 2019; Basel, Switzerland. Available at: https://www.urotoday.com/conference-highlights/apccc-2019/114634-apccc-2019-subgroup-analysis-of-mcrpc-trials.html.

44. Attard G., Borre M., Gurney H., Loriot Y., Andresen-Daniil C., Kalleda R. et al. Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J Clin Oncol. 2018;36(25):2639–2646. doi: 10.1200/JCO.2018.77.9827.

45. Khalaf D., Annala M., Finch D.L., Oja C.D., Vergidis J., Zulfiqar M. et al. Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): results for 2nd-line therapy. J Clin Oncol. 2018;36(15S):5015. doi: 10.1200/JCO.2018.36.15_suppl.5015.

46. Smith M.R., Saad F., Rathkopf D.E., Mulders P.F.A., de Bono J.S., Small E.J. et al. Clinical outcomes from androgen signaling-directed therapy after treatment with abiraterone acetate and prednisone in patients with metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-302. Eur Urol. 2017;72(1):10–13. doi: 10.1016/j.eururo.2017.03.007.

47. Zhang T., Dhawan M.S., Healy P., George D.J., Harrison M.R., Oldan J. et al. Exploring the clinical benefit of docetaxel or enzalutamide after disease progression during abiraterone acetate and prednisone treatment in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13(4):392–399. doi: 10.1016/j.clgc.2015.01.004.

48. Azad A.A., Eigl B.J., Murray R.N., Kollmannsberger C., Chi K.N. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol. 2015;67(1):23–29. doi: 10.1016/j.eururo.2014.06.045.

49. de Wit R., de Bono J., Sternberg C.N., Fizazi K., Tombal B., Wülfing C. et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381(26):2506–2518. doi: 10.1056/NEJMoa1911206.

50. de Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.P., Kocak I. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154. doi: 10.1016/ S0140-6736(10)61389-X.

51. Beer T.M., Armstrong A.J., Rathkopf D.E., Loriot Y., Sternberg C.N., Higano C.S. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433. doi: 10.1056/NEJMoa1405095.

52. Alekseev B.Y., Matveev V.B., Rusakov I.G., Volkova M.I., Karjakin O.B., Bolotina L.V. et al. Resolution on the results of the Meeting of Experts on the treatment of castrate-resistant prostate cancer. Onkourologiya = Cancer Urology. 2016;12(3):109–110. (In Russ.) doi: 10.17650/1726-9776-2016-12-3-109-110.

53. Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller K. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197. doi: 10.1056/NEJMoa1207506.

54. de Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L. et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005. doi: 10.1056/NEJMoa1014618.

55. Ryan C.J., Smith M.R., Fizazi K., Saad F., Mulders P.F., Sternberg C.N. et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–160. doi: 10.1016/S1470-2045(14)71205-7.